RJA
CLCD

Raymond James & Associates’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Raymond James & Associates’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,000
Closed -$343K – 3442
2016
Q3 		$343K Buy
+9,000
New +$133K ﹤0.01% 2531

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Raymond James & Associates's CLCD Position: Q4 2016 in Review

Raymond James & Associates sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2016, closing a stake of 9,000 shares — an estimated $343K sold.

Raymond James & Associates first reported a position in CLCD in Q3 2016 and held it in 1 quarter. The position peaked at $343K in Q3 2016. 76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

  • Raymond James & Associates reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 9,000 CoLucid Pharmaceuticals, Inc. shares in Q4 2016, an estimated $343K.
  • Raymond James & Associates first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Raymond James & Associates's CoLucid Pharmaceuticals, Inc. position peaked at $343K in Q3 2016.
  • 76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.